Industry news that matters to you.  Learn more

What, Where and How: Exploring Disease Predisposition to Deliver Personalized Medicine

Geneticists from the University of Geneva have taken an important step towards true predictive medicine. Exploring the links between diseases and tissue-specific gene activity, they have been able to build a model that constitutes a first step towards the identification of specific sequences in the non-coding genome signalling their pathogenicity in the context of a specific disease. In a second study, they went even further by associating particular disease risks – including schizophrenia, cardiovascular disease and diabetes – to the variability of genome activity in various cell types, with surprising results. Their discoveries, which can be read in two articles published in Nature Genetics, may very well revolutionize how each one of us, depending on our genome, manage our health.

Stroke Blood Test that Could Increase Use of Most Effective Treatment Five-fold

Researchers at the University of Geneva (UNIGE), in collaboration with UK company Proteome Sciences plc (PS) describe a simple blood test that could substantially increase the number of patients eligible for highly effective ischaemic stroke therapy in a landmark paper “Blood Glutathione S-Transferase-p (GSTP) as a Time Indicator of Stroke Onset”, published recently in the journal PLoS ONE.

Proteome Sciences Licenses Stroke Biomarker Portfolio to Randox

Proteome Sciences plc (“Proteome Sciences”), a global leader in protein biomarkers has today granted a non-exclusive license to Randox Laboratories (“Randox”) of Crumlin, UK for its portfolio of stroke biomarkers.

University of Geneva, Geneva University Hospitals and Swiss Institute of Bioinformatics Partner Up with Roche

The University of Geneva (UNIGE), Geneva University Hospitals (HUG) and the SIB Swiss Institute of Bioinformatics announced today the creation of a strategic collaboration with Roche in translational medical research. The initial focus of this collaborative platform will be on basic research, bioinformatics and biomarker development in cardiology, hematology, pathology and applied human toxicology.